Ajay Joseph, MD
Interventional Cardiology · Tulsa, OKNPI 1104180553
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,450 of the $7,888 with a category attached, or 81.8%. It is spread thinly across 44 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,589 and has fallen 76.4% since, to $610 in 2025. That places this record below the midpoint for interventional cardiology clinicians in OK, where the typical reported total is $7,360.
Across 308 payments — averaging $25.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Novartis$695
- Amgen$538
- Abiomed$445
- Cook Medical LLC$353
- Johnson & Johnson$342
- plus $4K from 38 others
What the payments were for
- Travel & lodging$1,34917%
- Food & beverage$6,45082%
- Education$881%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ANGIOJET$1,226
- FLOWTRIEVER CATHETER, S$294
- CT THROMBECTOMY SYSTEM KIT$294
- Cook Medical Peripheral Intervention$269
- Impella$147
- Acticor$139
- Edora$139
- BioMonitor$139
- Solia$139
- Rivacor$139
- Edwards SAPIEN 3 Transcatheter Heart Valve$115
- Saxenda$107
- General - Balloon Catheters$103
How this compares
$7,888 in reported general payments places this provider in the 50th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 556 | $552,265 |
| EntrestoSacubitril/Valsartan | 238 | $234,669 |
| XareltoRivaroxaban | 224 | $224,827 |
| JardianceEmpagliflozin | 100 | $108,260 |
| Repatha SureclickEvolocumab | 113 | $95,836 |
| Praluent PenAlirocumab | 63 | $42,282 |
| MultaqDronedarone Hcl | 15 | $18,301 |
| Atorvastatin Calcium | 455 | $12,112 |
| BrilintaTicagrelor | 14 | $9,200 |
| Rosuvastatin Calcium | 161 | $6,446 |
| Metoprolol Succinate | 321 | $5,428 |
| Carvedilol | 361 | $4,856 |
| Ezetimibe | 64 | $3,651 |
| ClopidogrelClopidogrel Bisulfate | 151 | $3,122 |
| Clonidine | 13 | $2,917 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $230 | $552,265556 claims |
| NovartisEntresto | $695 | $234,669238 claims |
| Johnson & JohnsonXarelto | $342 | $224,827224 claims |
| Boehringer IngelheimJardiance | $132 | $108,260100 claims |
| Sanofi-aventis U.S. LLCMultaq | $62 | $18,30115 claims |
| AstraZenecaBrilinta | $186 | $9,20014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Tulsa
- Kamran MuhammadTulsa$1.4M
- Stanley ZimmermanTulsa$93K
- Matthew ComstockTulsa$69K
- Wayne LeimbachTulsa$68K
- Tom HuTulsa$57K
- Eugene IchinoseTulsa$49K
- Poorya FazelTulsa$29K
- Tucker HarrisonTulsa$19K
- Andrew KurklinskyTulsa$15K
- Stewart KatzTulsa$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.